Abliva ^Investors

Abliva is an organization dedicated to developing medicines for the treatment of primary mitochondrial diseases. These diseases are rare, congenital, and often severe, resulting from dysfunctional mitochondria, the cell's energy provider. Abliva's portfolio consists of projects in various stages, from early discovery to clinical phases. Their goal is to provide effective treatments for these debilitating conditions and improve the lives of patients affected by primary mitochondrial diseases.